Cellceutix Phase 2 Trial Dose Escalates in 2nd Cohort for Brilacidin as a Drug Candidate for Ulcerative Colitis Pharmaceutical Investing
CymaBay Therapeutics Announces the Initiation of Phase 2 Study of Seladelpar (MBX-8025) in Patients with Primary Biliary Cholangitis Pharmaceutical Investing
Aclaris Therapeutics Initiates Phase 1 Clinical Trial for ATI-50001 for the Treatment of Alopecia Totalis and Alopecia Universalis Life Science Investing
Progenics Pharmaceuticals Announces First Patient Dosed in Phase 2/3 Clinical Trial of PSMA-Targeted PET/CT Imaging Agent PyL™ Life Science Investing
Kitov Successfully Completes All KIT-302 Testing Required for New Drug Application to US FDA Pharmaceutical Investing
Novartis Announces Zykadia® First-Line Study Results Showing 16.6 Month Progression-Free Survival in Patients with ALK+ Advanced NSCLC Life Science Investing
Reata Pharmaceuticals Announces Filing of Registration Statement for Proposed Public Offering Biotech Investing
Inovio MERS Vaccine Development to be Expanded with Funding from International Vaccine Institute Biotech Investing
AzurRx BioPharma Announces Agreement in Principle with TransChem for MTAN Inhibition Technology Biotech Investing
Cerecor Announces Top-Line Results from CERC-501 Phase 2 Study for Nicotine Withdrawal Biotech Investing
EyeGate Reports Positive Data from Third Stage of Phase 1b/2a Clinical Trial of EGP-437 in Cataract Surgery Patients Pharmaceutical Investing
